RIGL Insider Kamil Ali-Jackson Sells $88K of Stock
Kamil Ali-Jackson sold 2,500 shares of RIGL in a planned transaction on June 22, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals, Inc. ($RIGL) at an average price of $35, worth about $87,500, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $RIGL is up 9.3% after 1 week, up 5.8% after 1 month and up 28.7% to date (from the $35.73 close on Jun 22, 2026).
RIGL
Rigel Pharmaceuticals, Inc.
Key Points
- Kamil Ali-Jackson sold 2,500 shares of RIGL on June 22, 2026, at $35.00 each, totaling $87,500 in a planned sale.
- Shares of RIGL traded at $36.79 on Thursday with notable institutional activity from BlackRock and Armistice Capital.
- Analysts from HC Wainwright & Co. and Citigroup have maintained buy ratings with targets up to $81.00.
Get $RIGL trade alerts by text
We text you when insiders, Congress or big funds trade $RIGL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Rigel Pharmaceuticals, Inc. alert may contain errors. Disclosures
Kamil Ali-Jackson, an insider at RIGL, sold 2,500 shares of the company on June 22, 2026. This planned transaction was executed at an average price of $35.00 per share, amounting to a total value of $87,500.
Other Institutional Activity in RIGL
BlackRock, Inc. grew its holdings in RIGL by 104,697 shares, bringing its total to 1,768,907 shares valued at approximately $47.83 million. Armistice Capital, LLC significantly increased its stake by 444,000 shares, resulting in a total of 1,280,000 shares worth about $34.61 million, a 53.1% increase. Vanguard Capital Management LLC opened a new position with 764,193 shares valued at $20.66 million. Meanwhile, Acadian Asset Management LLC added 172,822 shares, ending with 666,426 shares worth $18.01 million, marking a 35.0% increase.
Rigel Pharmaceuticals, Inc. Stock Down 21.1%
On Thursday, RIGL shares were trading at $36.79. The stock has been experiencing some fluctuations with a current market cap and other specific financial metrics not provided. However, the institutional interest suggests a dynamic trading environment for RIGL.
Insider Buying and Selling at Rigel Pharmaceuticals, Inc.
In addition to Kamil Ali-Jackson's sale, several other insiders have been active. On June 17, 2026, Dean Schorno, EVP & Chief Financial Officer, along with Raymond Furey, David Santos, Raul Rodriguez, and Lisa Rojkjaer, acquired shares without a specified price, indicating potential confidence in the company's future performance.
Analysts Set New Price Targets
HC Wainwright & Co. reiterated a buy rating for RIGL on May 22, 2026, with a price target of $57.00. Citigroup maintained its buy rating across multiple reports, with the highest target set at $81.00 on May 13, 2026. These ratings reflect a positive outlook from analysts on RIGL's potential.
Bottom Line
The recent insider sale by Kamil Ali-Jackson, along with substantial institutional activity, highlights the active trading environment surrounding RIGL. Analysts remain optimistic, with several maintaining buy ratings and setting ambitious price targets. As always, it's important to remember that 13F filings and insider transactions are backward-looking and might not reflect the most current positions.
Related Filing Alerts
Source: Kamil Ali-Jackson's Form 4 filing on $RIGL (Jun 22, 2026). Find the original filing: RIGL Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts